Furthermore, we validate that miR-106b-5p promotes G1/S cell-cycle transition and sensitizes HCC cells to sorafenib via the BTG3/Bcl-xL/cyclinE1 pathway. This evidence concerns the gene BTG3 and hepatocellular carcinoma.